Brenda A. Schulman, Ph.D.

Photo of Brenda Schulman

TitleInvestigator, Howard Hughes Medical Institute
 Co-Director, Program in Molecular Oncology
DepartmentDepartment of Genetics/Tumor Cell Biology
 Department of Structural Biology
InstitutionSt. Jude Children's Research Hospital
AddressMS 311 Room D-5024E
 262 Danny Thomas Place
City, State, ZipMemphis, TN 38105
Phone(901) 495-5147
Research FieldBiochemistry
Award Year2002


The Schulman lab studies the structural basis for post-translational modification by ubiquitin and ubiquitin-like proteins (Ubls). Post-translational covalent attachment of Ubls to protein targets is a primary eukaryotic regulatory mechanism. There are more than a dozen Ubls in higher eukaryotes—such as ubiquitin, NEDD8, ISG15, and SUMO—that covalently modify myriad substrates. The best understood function of a Ubl modification is ubiquitin-mediated proteasomal degradation.  However, different Ubls alter the functions of their targets in different ways, such as by changing the target’s subcellular localization, enzymatic activity, or interactions with other proteins or DNA.  Moreover, defects in these pathways have been widely associated with diseases such as cancer, neurodegenerative disorders and viral infections. We believe that determining the mechanisms by which enzymes transfer Ubls will be of broad importance, much like studies of protein kinases have influenced our knowledge of signaling pathways and their roles in diseases. Toward this end, the goals of our research are (1) to understand the basic enzymatic mechanisms underlying Ubl attachment to targets, (2) to understand how Ubls are attached selectively, and (3) to understand mechanisms by which Ubl covalent attachment can change enzyme and target function.


2002 Scholars


Submit an update to this directory entry for Brenda A. Schulman, Ph.D.